Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ELTX
stocks logo

ELTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.445
-56.37%
--
--
-0.420
-51.72%
--
--
-0.370
-43.94%
Estimates Revision
The market is revising No Change the revenue expectations for Elicio Therapeutics, Inc. (ELTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -27.48%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-27.48%
In Past 3 Month
Wall Street analysts forecast ELTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELTX is 15.50 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ELTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELTX is 15.50 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.325
sliders
Low
13.00
Averages
15.50
High
18.00
Current: 8.325
sliders
Low
13.00
Averages
15.50
High
18.00
H.C. Wainwright
Buy
maintain
$10 -> $13
2025-07-17
Reason
H.C. Wainwright
Price Target
$10 -> $13
2025-07-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Elicio Therapeutics to $13 from $10 and keeps a Buy rating on the shares. The firm says investor focus is on the interim analysis from the randomized Phase 2 portion of the AMPLIFY-7P trial in Q3.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$10
2025-04-02
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$10
2025-04-02
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Elicio Therapeutics Inc (ELTX.O) is -5.24, compared to its 5-year average forward P/E of -2.73. For a more detailed relative valuation and DCF analysis to assess Elicio Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.73
Current PE
-5.24
Overvalued PE
-1.29
Undervalued PE
-4.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ELTX News & Events

Events Timeline

(ET)
2025-11-07
09:11:03
Elicio Therapeutics Reveals New Findings from Phase 2 AMPLIFY-7P Study
select
2025-10-27 (ET)
2025-10-27
08:06:59
Elicio Reveals Initial Findings from Phase 2 AMPLIFY-7P Study
select
2025-09-29 (ET)
2025-09-29
08:13:07
Elicio Therapeutics Launches Investigator-Led Phase 1 Trial for ELI-002 7P
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
09-17NASDAQ.COM
Elicio Announces Robust T Cell Responses in Phase 2 Cancer Vaccine Trial

  • Trial Results: Elicio Therapeutics announced that 99% of patients in its Phase 2 AMPLIFY-7P trial showed strong mKRAS-specific T cell responses after treatment with the investigational cancer vaccine ELI-002 7P, with immune responses increasing 145-fold from baseline.

  • Future Expectations: The company anticipates final disease-free survival data from the trial by the fourth quarter of 2025, and an independent monitoring committee has recommended that the trial continue without changes, indicating potential efficacy.

[object Object]
Preview
4.0
07-17Benzinga
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.

  • Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

[object Object]
Preview
1.0
06-17Newsfilter
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

  • Elicio Therapeutics KOL Event: Elicio Therapeutics will host a virtual event on June 25, 2025, to discuss the treatment landscape for mutant-KRAS driven pancreatic cancer, featuring insights from leading experts and focusing on their lead product candidate, ELI-002, which is currently in a Phase 2 trial.

  • ELI-002 and AMP Platform: ELI-002 is an investigational cancer vaccine targeting KRAS mutations, utilizing Elicio's proprietary amphiphile (AMP) platform designed to enhance immune responses by delivering therapeutics directly to lymph nodes, with plans for future expansion into other cancer indications.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Elicio Therapeutics Inc (ELTX) stock price today?

The current price of ELTX is 8.325 USD — it has increased 3.42 % in the last trading day.

arrow icon

What is Elicio Therapeutics Inc (ELTX)'s business?

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

arrow icon

What is the price predicton of ELTX Stock?

Wall Street analysts forecast ELTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELTX is 15.50 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Elicio Therapeutics Inc (ELTX)'s revenue for the last quarter?

Elicio Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Elicio Therapeutics Inc (ELTX)'s earnings per share (EPS) for the last quarter?

Elicio Therapeutics Inc. EPS for the last quarter amounts to -0.60 USD, decreased -56.83 % YoY.

arrow icon

What changes have occurred in the market's expectations for Elicio Therapeutics Inc (ELTX)'s fundamentals?

The market is revising No Change the revenue expectations for Elicio Therapeutics, Inc. (ELTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -27.48%.
arrow icon

How many employees does Elicio Therapeutics Inc (ELTX). have?

Elicio Therapeutics Inc (ELTX) has 32 emplpoyees as of December 05 2025.

arrow icon

What is Elicio Therapeutics Inc (ELTX) market cap?

Today ELTX has the market capitalization of 145.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free